Company / Working Capital
Kymera Therapeutics, Inc. Working Capital History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$788.0M
FY2025
5-year range
$319.6M / $788.0M
FY2021-FY2025
Trend
+78.1%
vs FY2024
Sector context
#51 of 213
Health Care
What the data says
Kymera Therapeutics, Inc.'s working capital of $788M is higher than 76% of companies in the Health Care sector (FY2025). Improved from $320M to $788M over the past 2 years.
Based on SEC 10-K filings.
$788M in FY2025 with a 5-year CAGR of +32.7%. Top quartile in the Health Care sector.
Improved from $320M to $788M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +31.3%
- 5-Year CAGR
- +32.7%
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 213This company $788.0M Sector average $934.6M
▼
-15.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +32.7%, indicating consistent growth.
- In FY2025, working capital increased 78.1% year-over-year.
- Ranks #51 out of 213 companies in the Health Care sector.
- Lowest working capital in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $788.0M | +78.1% |
| FY2024 | $442.5M | +38.4% |
| FY2023 | $319.6M | -8.2% |
| FY2022 | $348.1M | -3.0% |
| FY2021 | $358.7M | +87.1% |
| FY2020 | $191.7M | +229.0% |
| FY2019 | $58.3M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026